Skip to Content

Ampligen Approval Status

  • FDA approved: No
  • Brand name: Ampligen
  • Generic name: rintatolimod
  • Company: Hemispherx Biopharma, Inc.
  • Treatment for: Chronic Fatigue Syndrome

Ampligen (rintatolimod) is an experimental nucleic acid therapeutic in development for the treatment of a variety of chronic diseases and viral disorders.

Development Status and FDA Approval Process for Ampligen

Feb  9, 2015Hemispherx Biopharma Posts USAMRIID Ebola Study Concluding Ampligen Produced 100% Survival Rate in Rodents with 100% Mortality in Placebo
Dec  9, 2014Hemispherx Announces Data Showing Inhibition of Ebola by Ampligen Enlarged by Howard University Research
Feb  5, 2013Hemispherx Biopharma Receives Complete Response Letter From FDA on Ampligen New Drug Application for Chronic Fatigue Syndrome
Dec 27, 2012FDA Advisory Committee Makes Recommendations on Ampligen for Chronic Fatigue Syndrome
Oct 23, 2012Hemispherx Biopharma Announces FDA Confirms Advisory Committee Meeting on December 20, 2012
Sep 24, 2012Hemispherx Biopharma Announces FDA Advisory Committee Will Review Ampligen for Chronic Fatigue Syndrome
Aug 14, 2012FDA Accepts Complete Response Submission Regarding the Ampligen New Drug Application for Chronic Fatigue Syndrome
Aug  1, 2012Hemispherx Biopharma Files Complete Response With the FDA Regarding Its Ampligen New Drug Application for Chronic Fatigue Syndrome
Mar  7, 2008Hemispherx Biopharma Reaches Agreement With FDA on Specific Steps to Achieve Complete NDA on Proposed CFS Treatment Ampligen
Jan  9, 2008Hemispherx Biopharma Addresses FDA Questions On Ampligen NDA
Oct 11, 2007Hemispherx Biopharma Files New Drug Application for Ampligen as Treatment for Chronic Fatigue Syndrome

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.